Search

Qingyu Wu

from San Francisco, CA
Age ~33
Get Report
Also known as:
Qing Yu Wu
Related to:
Feng Liang, 61Fu Liang Wang, 66David WuZhaohui Zhu, 57Hanying Zhu, 60Ziqiang WuZiqiang Wu, 61Keyang Wu, 61Jiansen Zhu, 66
Connected to:
Aihua Wu, 40Ailsa T Wu, 53Alice H Wu, 55Alix S Wu, 52Amie Wu, 39Angela Y Wu, 72Anqi Wu, 44Anqiang Wu, 48Banting H Wu, 63Baodong Wu, 62

Qingyu Wu Phones & Addresses

  • San Francisco, CA
  • New York, NY
  • Plano, TX

Resumes

Resumes

Qingyu Wu Photo 1

Senior Graphic Designer

View page
Location:
New York, NY
Industry:
Graphic Design
Work:
Detao Masters Academy
Design Lecturer
Johnson & Johnson 2018 - 2018
Brand Designer
Various Projects Jun 2017 - Sep 2017
Graphic Designer
Mccabe Jun 2017 - Sep 2017
Freelance Graphic Designer
Cranbrook Academy of Art Sep 2016 - May 2017
International Representative
Education:
Cranbrook Academy of Art 2015 - 2017
Master of Fine Arts, Masters, Fine Arts, Graphic Design Virginia Commonwealth University 2011 - 2015
Bachelors, Bachelor of Fine Arts, Graphic Design Parsons School of Design - the New School 2014 - 2014
Skills:
Indesign
Illustrator
Photoshop
Photography
Adobe Creative Suite
Adobe Illustrator
Web Design
Print Design
Adobe Photoshop
Maya
Final Cut Pro
Screen Printing
Letterpress
Interaction Design
Mobile Applications
Magazine Design
Interests:
Arts and Culture
Languages:
English
Certifications:
Dean's List Commendation
Virginia Commonwealth University
Cranbrook Art Academy
Merit Scholarship
Qingyu Wu Photo 2

Qingyu Wu

View page
Location:
New York, NY
Industry:
Higher Education
Work:
Teneo Holdings
Investment Banking Analyst
Qingyu Wu Photo 3

Qingyu Wu

View page

Business Records

Name / Title
Company / Classification
Phones & Addresses
Qingyu Wu
Director
W&H GROUP, INC
2406 Brooke Ct, Carrollton, TX 75006

Publications

Us Patents

Modified Corin Molecules Having Substitute Activation Sequences And Uses Thereof

View page
US Patent:
7176013, Feb 13, 2007
Filed:
Jun 9, 2004
Appl. No.:
10/865978
Inventors:
Qingyu Wu - Lafayette CA, US
Assignee:
Schering Aktiengesellschaft - Berlin
International Classification:
C12N 9/64
C12N 15/57
C12N 15/62
C12N 15/79
A61K 38/48
US Classification:
435226, 435 691, 435 697, 4352523, 4353201, 435975, 424 9464, 536 232, 536 234
Abstract:
This invention relates to novel modified corin molecules, or fragments or derivatives thereof, comprising a substitute activation sequence. The modified corin molecules are cleaved at the substitute activation sequence, thereby generating activated corin molecules, or fragments or derivatives thereof, that exhibit the functional activity of naturally occurring, wild-type corin molecules. The modified corin molecules can be used to treat a variety of diseases or disorders, including congestive heart failure and acute myocardial infarction.

Control Sequences Of The Human Corin Gene

View page
US Patent:
20030223976, Dec 4, 2003
Filed:
May 28, 2003
Appl. No.:
10/447476
Inventors:
Junliang Pan - El Cerrito CA, US
Qingyu Wu - Lafayette CA, US
Assignee:
Schering Aktiengesellchaft - Berlin
International Classification:
A61K048/00
C12Q001/68
C07H021/04
US Classification:
424/093210, 514/044000, 435/006000, 536/023200
Abstract:
This invention provides a novel expression control region isolated from mammalian corin genes. This control region preferentially activates transcription in cardiac cells. Methods and compositions are provided to employ this control region for identification of agents capable of modulating corin expression and for treatment of cardiac disease.

Modified Hepsin Molecules Having A Substitute Activation Sequence And Uses Thereof

View page
US Patent:
20040132156, Jul 8, 2004
Filed:
Oct 2, 2003
Appl. No.:
10/678816
Inventors:
Gordon Parry - Oakland CA, US
David Vogel - Richmond CA, US
Marc Whitlow - Richmond CA, US
Qingyu Wu - Lafayette CA, US
Assignee:
Schering Aktiengesellschaft - Berlin
International Classification:
C12N009/64
C07H021/04
US Classification:
435/226000, 435/069100, 435/320100, 435/325000, 536/023200
Abstract:
The present invention provides modified hepsin molecules, or fragments or derivatives thereof, including those having a substitute activation sequence. The modified hepsin molecules are cleaved at the substitute activation sequence, thereby generating activated modified hepsin molecule, or fragments or derivatives thereof, that exhibit the functional activity of naturally-occurring, wild-type hepsin molecules.

Targeted Plasminogen Activator Fusion Proteins As Thromobolytic Agents

View page
US Patent:
20090286721, Nov 19, 2009
Filed:
Sep 6, 2005
Appl. No.:
11/817454
Inventors:
Junliang Pan - El Cerrito CA, US
Qingyu Wu - Lafayette CA, US
Achim Schuttler - Aachen, DE
Annemarie Schuttler - Aachen, DE
International Classification:
A61K 38/00
C07K 19/00
C07K 16/00
A61P 7/00
A61P 9/00
C07H 21/04
A61K 48/00
US Classification:
514 12, 530350, 5303911, 536 234, 514 44 R
Abstract:
This invention relates to novel fusion proteins, comprising a targeting protein and a plasminogen activator, preferably an antibody that binds to P-selectin, operably linked to the plasminogen activator DSPAalpha1, or analogs, fragments, derivatives, or variants thereof, which are useful as thrombolytic agents. Pharmaceutical compositions containing these fusion proteins, methods of using these fusion proteins as thrombolytic agents, and processes for synthesizing these fusion proteins are also described herein.

Knockout Mice And Their Progeny With A Disrupted Hepsin Gene

View page
US Patent:
59818301, Nov 9, 1999
Filed:
Dec 30, 1997
Appl. No.:
9/000846
Inventors:
Qingyu Wu - El Sobrante CA
Jasper E. Sadler - St. Louis MO
Assignee:
Schering Aktiengesellschaft - Berlin
Washington University - St. Louis MO
International Classification:
C12N 1509
C12N 1563
C12N 1500
C12N 500
US Classification:
800 18
Abstract:
The present invention provides a transgenic mouse comprising a disrupted hepsin gene. In particular, the invention provides methods of making the transgenic mouse comprising the disrupted hepsin gene by utilizing a hepsin targeting vector for homologous recombination in mouse embryonic stem cells. Also, nucleotide and amino acid hepsin sequences are disclosed.
Control profile
Qingyu Wu from San Francisco, CA, age ~33 Get Report